Searchable abstracts of presentations at key conferences in endocrinology

ea0065p199 | Metabolism and Obesity | SFEBES2019

Systemic and femoral adipose tissue-specific nontargeted plasma metabolome during acute hypercortisolaemia

Prete Alessandro , Dunn Warwick B , Manolopoulos Konstantinos

Background: Glucocorticoids have pleiotropic metabolic functions and acute glucocorticoid excess causes dramatic disruption of human metabolism. Whether glucocorticoids exert adipose tissue depot-specific effects on the nontargeted metabolome in unknown.Aim: Assess the nontargeted metabolome in the systemic circulation and in femoral adipose tissue-specific blood samples in response to physiological hyperinsulinaemia and acute hypercortisolaemia.<p c...

ea0038oc1.4 | Early Career Oral Communications | SFEBES2015

Adipose tissue-specific androgen generation fuels an adverse metabolic phenotype in patients with polycystic ovary syndrome

O'Reilly Michael , Kempegowda Punith , Gathercole Laura , Bujalska Iwona , Taylor Angela , Hughes Beverley , Dunn Warwick , Semple Robert , Tomlinson Jeremy , Arlt Wiebke

Insulin resistance and androgen excess are the cardinal features of polycystic ovary syndrome (PCOS). Severity of hyperandrogenism and metabolic dysfunction in PCOS are closely correlated, but underlying mechanisms remain poorly understood. Aldoketoreductase type 1C3 (AKR1C3) is a key source of adipose androgen generation, activating androstenedione to testosterone (T). We postulated that AKR1C3 plays a critical role linking androgen metabolism and metabolic ...

ea0049oc3.3 | Receptors &amp; Signalling | ECE2017

AKR1C3-mediated adipose androgen generation drives lipotoxicity in polycystic ovary syndrome

O'Reilly Michael , Kempegowda Punith , Walsh Mark , Taylor Angela , Manolopoulos Konstantinos , Allwood William , Semple Robert , Hebenstreit Daniel , Dunn Warwick , Tomlinson Jeremy , Arlt Wiebke

Polycystic ovary syndrome (PCOS) is prevalent metabolic disorder in women, associated with androgen excess and insulin resistance. These two major features are closely correlated, but the direction of causality remains unclear. Aldoketoreductase type 1C3 (AKR1C3) converts the androgen precursor androstenendione to testosterone (T), and is highly expressed in subcutaneous (SC) adipose tissue. We hypothesised that adipose tissue represents an important site linking androgen acti...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0065oc1.1 | Metabolism and Obesity | SFEBES2019

Intracrine activation of 11-oxygenated androgens by AKR1C3 modulates lipid metabolism in human female adipose tissue

Schiffer Lina , Sinclair Alexandra J , O'Reilly Michael W , Westgate Connar , Mashood Afeefa , Palmer Elliot , Gilligan Lorna C , Singhal Rishi , Taylor Angela E , Dunn Warwick B , Arlt Wiebke , Storbeck Karl-Heinz

Polycystic ovary syndrome (PCOS) affects 10% of women and is associated with an increased risk of type 2 diabetes and fatty liver disease. Androgen excess is an important driver of metabolic risk in PCOS. In adipose tissue from women with PCOS, increased activation of androstenedione (A4) to testosterone (T) by the enzyme AKR1C3 results in systemic lipotoxicity. Recent in-vitro studies also demonstrated that T and 11-ketotestosterone (11KT) activate the androgen recep...

ea0038oc2.1 | Translational pathophysiology and therapeutics | SFEBES2015

Dual 5-α reductase inhibition promotes hepatic lipid accumulation in man as a result of changes to lipid metabolism in adipose tissue and the liver

Hazlehurst Jonathan , Oprescu Andrei , Nikolaou Nikolaos , Guida Riccardo Di , Grinbergs Annabel , Davies Nigel , Flintham Robert , Armstrong Matthew , Taylor Angela , Hughes Beverly , Yu Jinglei , Hodson Leanne , Dunn Warwick , Tomlinson Jeremy

Background and aims: 5α reductase 1 and 2 (SRD5A1 (expressed in liver and adipose), SRD5A2 (expressed in liver) inactivate cortisol to 5α-dihydrocortisol in addition to their role in the generation of dihydrotestosterone and therefore regulate the tissue availability of cortisol. Dutasteride (dual SRD5A1 and SRD5A2 inhibitor) and Finasteride (selective SRD5A2 inhibitor) are commonly prescribed, but their potential metabolic effects have only recently been identified....

ea0056gp23 | Adrenal clinical | ECE2018

Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela , Doig Craig , Walsh Mark , Meimaridou Eirini , Jenkinson Carl , Rodriguez-Blanco Giovanny , Ronchi Cristina , Jaffri Alisha , Metherell Louise , Hebenstreit Daniel , Dunn Warwick , Arlt Wiebke , Foster Paul

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating human NNT mutations result in congenital adrenal insufficiency. We hypothesized NNT silencing in ACC cells will i...

ea0086oc4.4 | Adrenal and Cardiovascular | SFEBES2022

Steroid and global metabolome in benign adrenal tumours with mild autonomous cortisol secretion: analysis by mass spectrometry and machine learning to understand metabolic risk

Prete Alessandro , Abdi Lida , Canducci Marco , Taylor Angela E. , Bancos Irina , Gilligan Lorna C. , Jenkinson Carl , Albors-Zumel Ariadna , van den Brandhof Elina , Zhang Yuanqing , Chortis Vasileios , Tsagarakis Stylianos , Lang Katharina , Macech Magdalena , Delivanis Danae A. , Pupovac Ivana D. , Reimondo Giuseppe , Marina Ljiljana V. , Deutschbein Timo , Balomenaki Maria , O'Reilly Michael W. , Bednarczuk Tomasz , Zhang Catherine D. , Dusek Tina , Diamantopoulos Aristidis , Asia Miriam , Kondracka Agnieszka , Li Dingfeng , Masjkur Jimmy R. , Quinkler Marcus , Ueland Grethe AE. , Conall Dennedy M. , Beuschlein Felix , Tabarin Antoine , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Kastelan Darko , Young Jr William F. , Manolopoulos Konstantinos M. , Ambroziak Urszula , Vassiliadi Dimitra A. , Sitch Alice J. , Tino Peter , Biehl Michael , Dunn Warwick B. , Arlt Wiebke

Background: Benign adrenal tumours are found in 3-10% of adults and can be non-functioning (NFAT) or associated with adrenal hormone excess. Analysing 1305 prospectively recruited patients with benign adrenal tumours, we recently demonstrated that 45% had mild autonomous cortisol secretion (MACS), i.e. biochemical cortisol excess without signs of Cushing’s syndrome (CS). MACS increases the prevalence and severity of hypertension and type 2 diabetes (Ann Int Med. 2022 Doi:...